期刊
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
卷 63, 期 4, 页码 302-313出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/FJC.0000000000000054
关键词
heart failure; metabolism
资金
- National Institutes of Health [HL-080144, HL-0980842, HL-100401]
- Cancer Prevention and Research Institute of Texas CPRIT (CPRIT) [RP110486P3]
- AHA DeHaan Foundation [0970518N]
- Fondation Leducq [11CVD04]
- AHA [10POST4320009]
Heart failure is a leading cause of morbidity and mortality worldwide, currently affecting 5 million Americans. A syndrome defined on clinical terms, heart failure is the end result of events occurring in multiple heart diseases, including hypertension, myocardial infarction, genetic mutations and diabetes, and metabolic dysregulation, is a hallmark feature. Mounting evidence from clinical and preclinical studies suggests strongly that fatty acid uptake and oxidation are adversely affected, especially in end-stage heart failure. Moreover, metabolic flexibility, the heart's ability to move freely among diverse energy substrates, is impaired in heart failure. Indeed, impairment of the heart's ability to adapt to its metabolic milieu and associated metabolic derangement are important contributing factors in the heart failure pathogenesis. Elucidation of molecular mechanisms governing metabolic control in heart failure will provide critical insights into disease initiation and progression, raising the prospect of advances with clinical relevance.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据